@GiddyYup to answer your statement of going 3000% up, I do...

@GiddyYup to answer your statement of going 3000% up, I do remember back in February 2021 when Gilead pay US$ 725 Million dollars + double digit royalties to Gritstone for HIV phase clinical 1. The share price in two days touched $35 per share making the company worth more than US3.5 billion dollars. After more than 2 years the share price is down to $2.19 per share.
So if Biotron were to do a partnership with a BP anything is possible.
Below was the terms of the deal back in February 2021.
Under the terms of the deal, Gilead is paying Gritstone $30 million in cash up front and a $30 million equity investment. Gilead will handle a Phase I trial for the HIV-specific vaccine and will hold an exclusive option for an exclusive license to develop and commercialize it beyond Phase I. Gritstone will be up for an additional $725 million in regulatory and commercial milestones, as well as mid-single-digit to low double-digit tiered royalties on net sales.